< Back to previous page
Researcher
Yani Berckmans
- Disciplines:Cancer therapy
Affiliations
- Laboratory for Tumor Immunology and Immunotherapy (Division)
Member
From1 Sep 2021 → Today
Projects
1 - 1 of 1
- Preclinical evaluation of novel radionuclide therapies in different cancer modelsFrom8 Jul 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
Publications
1 - 6 of 6
- TIM3 Checkpoint Inhibition Fails to Prolong Survival in Ovarian Cancer-Bearing Mice.(2024)
Authors: Yani Berckmans, Jolien Ceusters, Ignace Vergote, An Coosemans
Pages: 1147 - Toward more accurate preclinical glioblastoma modeling: Reverse translation of clinical standard of care in a glioblastoma mouse model.(2024)
Authors: Yani Berckmans, Kim De Keersmaecker, An Coosemans
Pages: 381 - 397 - Drug Repurposing for Targeting Myeloid-Derived Suppressor-Cell-Generated Immunosuppression in Ovarian Cancer: A Literature Review of Potential Candidates(2023)
Authors: Yani Berckmans, Yannick Hoffert, Erwin Dreesen, An Coosemans
- Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancer(2021)
Authors: Jenny Sprooten, Ann Vankerckhoven, Isaure Vanmeerbeek, Yani Berckmans, Roxanne Wouters, Thaïs Baert, Tom Bourne, Wouter Froyman, Dominique Schols, Patrizia Agostinis, et al.
- Preclinical studies performed in appropriate models could help identify optimal timing of combined chemotherapy and immunotherapy
Authors: Yani Berckmans, Jolien Ceusters, Roxanne Wouters, An Coosemans
- Intraperitoneal alpha therapy with 224Ra-labeled microparticles combined with chemotherapy in an ovarian cancer mouse model
Authors: Roxanne Wouters, Yani Berckmans, Jolien Ceusters, Ignace Vergote, An Coosemans